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25 years, the profession has made tremendous gains, not only in acceptance on the part of the medical profession, third-party payers, and consumers, but also in establishing clinical pharmacy as an independent, value-added component of the health care system. Yet, the need to provide evidence of the economic benefit of clinical pharmacy services has not lessened with these advances. To the contrary, everpresent efforts to reduce health care spending have required the near continuous evaluation of these programs.
Articles on the economic impact of clinical pharmacy services represent a unique resource for the pharmacy manager or clinician who may be in the position of initiating, defending, or expanding such programs. Still, the volume of published literature, along with diversity of methods and quality of analysis, makes it difficult to identify applicable articles and interpret the findings. As a result, efforts have been made to summarize the literature in a format that is easier for the busy practitioner to access. The American College of Clinical Pharmacy (ACCP) has been integral to these efforts by sponsoring two key reviews of the literature. The first, printed in 1989, summarized the literature published before 1988. 2 The second ACCPsponsored work reviewed economic evaluations of clinical pharmacy services published between 1988 and 1995. 3 Other similar reviews that cover differing time ranges also have been published. [4] [5] [6] Since the publication of these reviews, additional primary articles have continued to appear in the pharmacy literature. In fact, some very large and important studies have been conducted over the past 5 years that have advanced our understanding of issues pertinent to the economic impact of clinical pharmacy services. 7, 8 Because a need exists for a comprehensive review of these recent studies, the ACCP Board of Regents again charged a group of individuals, in this case the 2002 Task Force on Economic Evaluation of Clinical Pharmacy Services, to summarize and interpret this literature. Objectives for the group were to summarize and evaluate the literature published from 1996-2000 that assessed the economic impact of clinical pharmacy services and to provide guidance on methodologic considerations to individuals performing such research, as well as recommendations for future research.
Methods
A search of two literature databases (MEDLINE and International Pharmaceutical Abstracts) was conducted to identify articles published between January 1996 and December 2000 (inclusive). The beginning date of January 1996 was selected because the previous ACCP review was inclusive through December 1995. 3 Both medical subject headings and free text search terms were used to identify original economic evaluations of clinical pharmacy services. Search terms were clinical pharmacy services, cost, cost analysis, cost benefit, cost-effectiveness, cost-utility analysis, economic evaluation, outcomes analysis, pharmacy services, outcomes, and programs. Where possible, the search was filtered to exclude non-English articles, review articles, editorials, and other incomplete or unoriginal works.
All citations identified were screened for inclusion by reviewing titles and abstracts. Those articles for which abstracts were not available from the electronic databases or that did not have abstracts were collected manually and screened for inclusion. Inclusion criteria were English language, original evaluation, publication date between January 1996 and December 2000 inclusive, assessment of a clinical pharmacy service (defined as a patient-level interaction, and not including policy-type interventions unless accompanied by a patient-level interaction), and some form of economic assessment (measurement of either costs to provide the service or economic outcomes, or both). Not included were unoriginal work (reviews, editorials, letters) or studies published only in abstract form. Studies that evaluated only clinical or humanistic outcomes, without an economic assessment, were excluded. After reviewing titles and abstracts, a hard copy of each article that met the inclusion criteria was obtained for full review.
In addition to the articles identified by the literature database search, several other methods were used to find pertinent literature. First, the authors examined personal files for yet ECONOMIC BENEFIT OF CLINICAL PHARMACY SERVICES Schumock et al unidentified articles. Second, the authors examined the bibliographies of included articles and of review articles to identify cited works. Third, the authors sent an e-mail message to members of all ACCP practice research networks (by means of the listserves for those groups) requesting that members "nominate" articles that met the inclusion criteria. Fourth, a search of a science citation database (Web of Science) was conducted to identify articles that referenced previous reviews. [2] [3] [4] [5] [6] Articles identified through these methods again were collected and screened for inclusion, and added to the set of articles subjected to full review.
In the full review process, each paper was randomly assigned to at least two of six reviewers who were to confirm inclusion criteria, abstract key information, and assess the quality of each article. Reviewers were blinded to authors' names and affiliations, and journal of publication. Reviews were recorded on a standard report form and entered into a database for analysis. Discrepancies between reviewers were arbitrated by group consensus. Major categories of data abstracted were study setting, service type, objective(s), methods, and results.
Each article was assessed for the type of evaluation and categorized as shown in Table 1 by using criteria previously adapted. 9 Two factors were considered in determining the type of evaluation: the presence of two or more alternatives and the consideration of both input cost(s) and outcome(s). Evaluations that included two or more alternatives (i.e., concurrent control group, historical control, and a before and after design) were considered "analyses," whereas those that did not include a comparison were labeled "descriptions." Before and after designs were differentiated from historical control designs in the temporal relationship to the intervention under study. If a study compared measurements taken immediately before an intervention and immediately after, it was coded as a before and after design. If a longer period of time elapsed between comparison groups (e.g., comparing data from the study period to the same month 1 year earlier), the study was defined as a historical control. Some studies used a before and after or a historical design in addition to a concurrent control group. Each evaluation was classified as one of the following: cost description, outcome description, cost analysis, outcome analysis, cost and outcome description, or full economic analysis. Those articles considered full economic analyses were subcategorized by type; the subcategories were cost-minimization analysis, cost-benefit analysis, cost-effectiveness analysis, and costutility analysis.
Articles were classified both by setting of evaluation and by type of clinical pharmacy service. Five major categories used to classify articles by type of clinical pharmacy service were defined as follows: disease management-a clinical pharmacy service primarily directed at patients with a specific disease state or diagnosis, such as an asthma management program; general pharmacotherapeutic monitoring-a clinical pharmacy service that encompassed a broad range of activities based primarily on the needs of an assigned group of patients, with services provided such as patient drug regimen review and recommendation, adverse drug reaction monitoring, drug interaction assessment, formulary compliance, and rounding with physicians; pharmacokinetic monitoring-a clinical pharmacy service that primarily involved evaluation of anticipated or actual serum drug concentrations and provision of subsequent dosing recommendations; targeted drug program-a clinical pharmacy service that primarily focused on a single drug or class of drugs and may have included predefined guidelines for provision of alternative therapy or 115 dosing recommendations, such as intravenous to oral switch recommendations for antibiotics; and patient education program or cognitive servicea clinical pharmacy service that primarily instructed patients on the proper administration of drugs and/or identified drug-related problems. Descriptive statistics were used to profile and characterize the articles within each data field abstracted by the reviewers. Study results were scrutinized carefully by the reviewers. Benefit:cost ratios were calculated by the reviewers if not provided by the author(s) and if appropriate to do so. The benefit:cost ratio (financial benefit/dollar invested to provide the service) was calculated by dividing reported total costs to provide the clinical pharmacy service described by the reported gross economic benefits derived from the service for the same time period. Benefit:cost ratios were pooled from applicable articles to calculate an overall mean value. The median benefit:cost ratio from the pooled studies also was identified. Figure 1 illustrates the results of the search and screening process: 1465 citations were identified through the initial electronic literature database search, 3 articles were added from the files of the authors, 2 were obtained through requests of ACCP members, 5 were added through the secondary search of the bibliographies of included articles, and 46 were added from a search of a science citation database, for a total of 1521 articles. A preliminary review of the titles and abstracts of these articles identified 1435 that did not meet the primary inclusion criteria. The most common reason for exclusion was failure to meet the definition of a clinical pharmacy service. Many citations that were published only in abstract form were also excluded. Thus, 86 articles were subjected to full review. During full review, 20 articles were identified as not meeting the inclusion criteria. In addition, one article was removed because it was based on the same data as a previously included study. 10 Further, six articles [11] [12] [13] [14] [15] [16] were excluded from the final group because these studies were based on secondary data (three articles) or derived from modeling techniques where data evaluated were not from an actual practice site (three articles); however, these articles were deemed important and are summarized separately.
Results

Included Articles
Appendix 1 describes the final set of 59 included articles. These articles are sorted first by the setting of the evaluation and then by the type of clinical pharmacy service described in the evaluation. Articles from pharmacy-based journals dominated the set of included studies. The most common journal source was American Journal of Health-System Pharmacy (19 articles, 32%). Pharmacotherapy (8 articles, 14%), Annals of Pharmacotherapy (5 articles, 8%), and Hospital Pharmacy (4 articles, 7%) also were common. Twelve articles were published in nonpharmacy journals. Most studies (51 articles, 86%) were conducted in the United States. Studies also were conducted in Australia (2 articles) and in Canada, Greece, Japan, the Netherlands, Spain, Table 2 ). The setting of most studies was either a community or a university hospital. Veterans Affairs or government clinics, community pharmacies, and hospital-associated clinics also were common. Other settings were freestanding clinics, physicians' offices, health maintenance organizations, long-term or intermediate care facilities, and Veterans Affairs or government hospitals.
The most common type of pharmacy service evaluated was general pharmacotherapeutic monitoring, followed by target drug programs (Table 3) . Disease management and patient education or cognitive services were evaluated in 10% of studies each. Table 4 summarizes the analytic methods used in the included articles. Fourteen studies (24%) included both an alternative or comparison group and measurement of both costs and outcomes (i.e., full economic analysis). The remaining articles consisted of less rigorous analytic methods. The most common of these, and the most common overall, was outcomes analyses (36%).
The study design of the included articles was further analyzed by considering the use of a comparison group(s) (or alternatives) and by the types of input costs and economic end points measured. Most studies (40 articles, 68%) included a comparison group, whereas 19 (32%) did not and therefore were considered to be descriptive in nature. Articles with study designs that included a comparison group used a concurrent control group (25 articles, 42%), a before and after design (11 articles, 19%) , or a historical control group (9 articles, 15%).
Most studies (31 articles, 52%) did not evaluate the cost of providing the clinical service as part of the economic evaluation of that service, whereas some (28 articles, 47%) did consider the cost to provide the service. Of studies that did consider some input costs, the most common costs assessed were those of personnel. On the other side of the equation, most studies did evaluate the economic outcomes or consequences of the service evaluated. Most commonly, this was done in terms of drug costs avoided or reduced health care expenditures. Many studies also measured clinical or humanistic outcomes. When measured, clinical and humanistic outcomes tended to be positive or neutral; those results are not provided here.
Most studies (50 articles, 85%) described a beneficial economic impact of the clinical pharmacy service evaluated. More notable, of the studies that included both investment costs and economic benefits, as well as an alternative, 100% demonstrated positive findings. Findings from these studies often were expressed as net savings over the study period (or annualized), as net savings adjusted/patient, and/or as a benefit:cost ratio.
In only five articles did authors report a benefit:cost ratio; however, in an additional 11 articles the reviewers were able to calculate a benefit:cost ratio from the results provided (Table  5 ). The benefit:cost ratios ranged from 1.74:1-17.0:1, with the median being 4.68:1 and the mean being 5.54:1. Although the mean and medians are similar, the median was considered more representative of the group based on the distribution of the benefit:cost ratios from the different studies.
Other Relevant Articles
The six articles analyzed separately from those listed in Appendix 1 represent important contributions to the literature on the economic impact of clinical pharmacy services, and the current review would be remiss if these studies were not included. All six studies were conducted by using United States data sources, and together they span the key health care settings, including ambulatory or outpatient settings, hospitals, and nursing facilities. Two articles, based on widely cited cost-ofillness studies, assessed the potential national impact of clinical pharmacy services on reducing drug-related problems. 11, 12 One article evaluated pharmaceutical care in the U.S. ambulatory population, and the other evaluated consultant pharmacist services in U.S. nursing facilities. Data for the analyses came from previously published studies that used decision models to estimate the cost of drug-related problems. 76, 77 An expert panel was used to determine conditional probabilities, and health care utilization and associated costs were estimated and/or derived from available statistical reports.
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Providing clinical pharmacy services in these environments was estimated to be economically beneficial. The authors estimated that if all patients received pharmaceutical care in the ambulatory care setting, $45.6 billion (in 1995 U.S. dollars) in direct health care costs would be avoided. Even when the fee associated with the provision of pharmaceutical care was increased 4-fold, the estimated cost avoidance changed only slightly. In the nursing facility study, the annual cost of drug-related problems/resident decreased from an estimated $235 without consultant pharmacists to $162 with consultant pharmacists (in 1994 U.S. dollars). For all nursing facility residents in the United States, the total cost of managing drug-related morbidity and mortality was $6.64 billion and $9.64 billion with and without consultant pharmacists, respectively.
In another study that used a modeling methodology (Markov modeling), 13 the evaluation was designed to assess the impact of academic detailing by clinical pharmacists in an outpatient practice setting in three hypothetical cohorts of patients with comorbid disease (diabetic nephropathy, myocardial infarction, or left ventricular dysfunction). Drug utilization rates, quality-of-life utility values, and probabilities were derived from previously published articles. Charges were used in lieu of costs and were estimated by professional coders based on usual and customary rates derived from Medicare diagnosis-related groups and other sources. Compared with usual practice, the presence of an academic detailing clinical pharmacist netted a cost savings/quality-adjusted life year.
One group of authors conducted three important cross-sectional studies of clinical pharmacy services in U.S. hospitals. [14] [15] [16] In each study, data from hospitals across the country were obtained from secondary sources (American Hospital Association Abridged Guide to the Health Care Field, National Survey of Clinical Pharmacy Services, and/or Medicare) and analyzed by means of multiple regression for associations between the presence of clinical pharmacy 118 The first of these studies demonstrated an association between four specific types of clinical pharmacy services (clinical research, drug information, admission drug histories, and cardiopulmonary resuscitation team participation) and reduced mortality. Cost-effectiveness ratios for these services also were estimated; these ranged from $28.92 (clinical research) to $192.58 (drug information) per death avoided. The second study demonstrated an association between clinical pharmacy services (in-service education, drug information, drug protocol management, and admission drug histories) and hospital drug costs. Reductions in drug costs/occupied bed for hospitals with versus those without these services ranged from $490.96 for in-service education to $1961.55 for drug information. The benefit:cost ratios for each service also were estimated; these ranged from $23.80:1 (drug histories) to $83.23:1 (drug protocol management). The third study by these authors demonstrated an association between six different clinical pharmacy services and reductions in the total cost of hospital care (drug therapy evaluation, drug information, adverse drug reaction monitoring, drug protocol management, medical rounds participation, and admission drug histories). Benefit:cost ratios were estimated for each service; these ranged from $31.92:1 (drug therapy evaluation) to $2988.57:1 (adverse-reaction monitoring). Although the benefit:cost values from these studies are impressive, they should be interpreted in the context of the study design, which was not to determine causation but rather to determine association between clinical pharmacy services and cost reduction.
Discussion
Assessment of the Literature
This review provides evidence of the continued economic value of clinical pharmacy services. The number of articles published on this topic has remained constant over the past 13 years (mean ± SD of 13.0 ± 6.1 articles/yr from 1996-2000 based on the 59 included articles and 6 additional studies in the current review and a mean of 13.0 ± 5.4 articles/yr from 1988-1995), but the quality of these studies has improved somewhat compared with those of the previous review. A greater percentage of studies in the current review included a comparison group and measured both costs and outcomes compared with those in the previous review (23.7% vs 18.3%). Further, of those that used less rigorous designs, researchers were more likely than in the past to include a comparison group (67.8% vs 58.6%), a key factor in the ability to prove the effect of an intervention. More studies also included the cost or investment required to provide clinical pharmacy services compared with the studies in the previous review (47.4% vs 31.7%). Inclusion of input costs is required to determine the true net benefit of a clinical service. These improvements may reflect adoption of specific recommendations made in the previous review regarding the design of such studies, or may reflect a greater general understanding on the part of the profession of study designs relevant to the discipline of pharmacoeconomics and outcomes research as recommend by other authors. 78, 79 However, despite these advances, there remains ample opportunity for continued improvement in the quality of studies of clinical pharmacy services. Further recommendations with respect to study design are provided later.
Changes have occurred in the setting in which economic evaluations of clinical pharmacy services are being conducted. The current review identified a substantial shift toward the outpatient setting and practice sites other than hospitals. A greater percentage of studies were conducted in community pharmacies and clinics, compared with the studies in the previous review (40.7% vs 18.3%). The current review also identified studies conducted in health maintenance organizations and in long-term and intermediate care facilities. Conducting studies in settings other than the traditional hospital site was a recommendation made in the previous review. Furthermore, this shift likely reflects a general movement in the profession. Clinical pharmacy services first developed in the hospital setting and have moved gradually to other settings. However, in the past decade especially, a great deal of effort has been directed toward the expansion of clinical services in the ambulatory care and community pharmacy settings.
Also, a shift was noted in the type of clinical pharmacy services evaluated. A greater percentage of studies in this review were of general or comprehensive pharmacotherapeutic services (47.7% vs 36.5%) or disease management programs (10.2% vs 3.8%), whereas a decrease was noted in evaluations of specialized or targeted types of interventions, such as pharmacokinetic services (1.7% vs 12.5%) or targeted drug programs (20.3% vs 47.1%). Reflective of the shift toward community pharmacy, this review also included evaluations of "cognitive pharmacy services," not seen in the previous review. These changes may be attributable to the profession-wide movement toward greater responsibility for outcomes of drug therapy (or pharmaceutical care) and are likely interrelated with the shift toward nonhospital practice sites. 80 Most studies identified in this review were conducted in the United States. However, compared with the studies in the previous review, a greater proportion of studies in the current review were conducted in other countries (though, except for the United States, only Australia is represented by more than one study). This is a positive finding that may portend a greater diversity of studies in the future. It also likely reflects a general trend of expansion of clinical pharmacy services outside the United States. Clinical pharmacy services first developed in the United States but gradually have been adopted by other countries, first by Canada, then Europe and Australia, and more recently Asia.
Most studies identified in the current review reported a positive economic impact of clinical pharmacy services, and in all cases those studies using better economic methodologies demonstrated positive results. The benefit:cost ratios of applicable articles included in Appendix 1 are comparable to those of the previous review. Although the mean benefit:cost ratio in the previous review (16.70:1) was much higher than that reported in the current review, the median values are similar (4.68:1 for the current review vs 4.09:1 for the previous review). The mean value reported in the previous review was skewed upward by a single study. 81 Regardless, the economic benefit of clinical pharmacy services across a variety of practice sites and types of clinical pharmacy services reviewed here is well in excess of the costs required to provide those services. For every $1 invested in clinical pharmacy services in the studies reviewed, more than $4 in benefit is expected.
The ability of readers to generalize these results is dependent on many factors, including the way in which results are expressed, comparability of the patient population, and the type of service evaluated. Clinical pharmacy services are highly dependent on internal factors, such as the characteristics of the practice setting or skill of the individual practitioner(s). Nevertheless, pharmacy managers and clinicians should use the results of previously published evaluations and benefit from the positive experience of others.
Limitations
This review in which economic assessments of clinical pharmacy services were evaluated provides a resource for readers to access the primary literature on this subject. However, the limitations of this review should be considered and the findings interpreted correspondingly. Several limitations are noteworthy.
First, the articles identified represent only those published in the standard literature. We did not consider unpublished papers; therefore, our results may be subject to publication bias (the tendency to publish only positive results). The large number of studies on this topic that were presented in abstract form and never published as complete articles may be evidence of this type of bias.
Second, the literature databases used to identify potential articles for this review, along with the search strategy, may have affected the quantity and types of articles identified. Every effort was made to ensure that the search strategy was as comprehensive as possible.
Third, in some cases, the included articles lacked description of data important to our analysis (reporting bias) and thus may have altered our results. No effort was made to contact authors regarding missing data.
Fourth, many of the articles we reviewed had objectives in addition to or other than that of economic evaluation, and although economic impact may have been part of the study, the evaluation may not have been designed specifically for that purpose. Our assessment of studies was restricted to the economic evaluation conducted. We did not report clinical and/or humanistic outcomes measured in the studies reviewed; more thorough analyses of these outcomes can be found elsewhere. 82, 83 Fifth, in this review, we classified cost savings resulting from clinical pharmacy services as economic outcomes or benefits. Because the main purpose of this evaluation was to investigate the economic impact of clinical pharmacy services, we chose to include the investment required to provide services but to separate that investment from the economic effect of those services. This approach is consistent with that used by many of the authors ECONOMIC BENEFIT OF CLINICAL PHARMACY SERVICES Schumock et al of the studies we reviewed, though it may differ from more traditional cost-effectiveness analyses in which economic outcome variables are considered costs. 84 Last, the mean benefit:cost ratio from pooled studies reported here should be considered cautiously. Studies from which benefit:cost ratios were derived varied in terms of patient population, practice setting, type of clinical service evaluated, and study design. Further, the studies used to derive this ratio were not truly experimental in terms of study design, but instead were quasiexperimental or preexperimental designs. The heterogeneity of these studies reduces the reliability of the mean value.
Recommendations for Future Research
Although significant gains have been made in the quality of economic assessments of clinical pharmacy services, opportunities still exist to improve the study designs used in these evaluations. Studies of this type are dependent on the ability of the particular design to establish a relationship between the intervention(s) and the resultant observed outcome(s). Several archetypical study designs (experimental, quasiexperimental, and preexperimental) have been described and are illustrated in Table 6 . 85 Future efforts to contribute in a meaningful way to the body of evidence surrounding the value of clinical pharmacy services should be made with an appreciation of the strengths and weaknesses of these study designs. Several recommendations for future research deal with considerations of study design.
Studies that aim to establish a causal relationship (e.g., evaluate whether a program has made a difference) must address the issue of internal validity. The key question of internal validity is whether observed changes can be attributed to the program (or intervention) and not to other possible causes or alternative explanations. Several conditions need to be met to establish a causal relationship, including temporal precedence (shows that the program happened before the effect), covariation of cause and effect (when program is present, effect is present and 121 when program is absent, effect is absent), and exclusion of other plausible explanations. Potential threats to internal validity may arise from multiple sources. Threats that apply to studies when a single group receives a program with no comparator include history (events that take place during the study that might have an effect on the outcome), maturation (changes that subjects being studied undergo during the course of the study that might have an effect on the outcome), and regression to the mean (a statistical phenomenon that occurs whenever a nonrandom sample from a population is studied with two measures that are imperfectly correlated). These threats can be avoided by using a comparison (or control) group, but this leads to other threats. In studies with a control group, selection bias is the primary threat and may exist when any factor other than the program leads to posttest differences between groups. Randomization is done to reduce the possibility of selection bias.
Incorporating all desired elements of a proper study design into an evaluation of a clinical pharmacy service is often difficult. Selection of an appropriate control group and randomization in particular may be problematic. One study included in our review provides a good model for study design. In this study, the authors used a quasiexperimental design to evaluate pharmaceutical care in a Medicaid population. 48 Baseline data were measured for two groups (intervention and control) before the intervention, which was applied to only one cohort (intervention group), followed by another period of observation and measurement. The primary outcome evaluation was conducted between the two cohorts on the difference in relative change between baseline and postintervention periods. Though not randomized, this study is a good example of the use of a control and sequence of observation.
Whereas a rigorous study design may be considered ideal, there are disadvantages to consider. Such a design requires the availability of two distinct cohorts, does not preclude the possibility that the nonintervention group may become "contaminated" by the changes made in the intervention group, and may be relatively expensive and time-consuming to conduct. As investigators make study design decisions, they are forced to compromise on various design elements, often choosing less rigorous designs in the interest of feasibility and practicality.
Once the study is complete, investigators should consider additional factors that increase the credibility of their results. Articulating the purpose of the analysis in explicit terms (both when proposing the study and reporting its results) will assist the investigator in ensuring that the study is designed appropriately and will allow readers to more easily understand and apply the results. Also, greater attention must be paid to measures of cost, both in terms of the resources needed to conduct the clinical pharmacy intervention and the measure of cost as a consequence. Surprisingly, the investment required to provide clinical pharmacy services (e.g., personnel) was not included in just over 50% of the studies we reviewed. This is a critical component in the determination of net benefits and must be included in all future studies.
With regard to the measurement of economic consequences of clinical pharmacy services, many evaluations are based on the "cost of what might have been" had the intervention not occurred. For example, if an intervention is performed that discontinues a potentially harmful or costly therapy, this method assumes that the change would not have been made otherwise and therefore the service should be credited with improving outcomes or reducing cost. However, the impact of these assumptions is rarely measured (with sensitivity analysis) and may be the single most important vulnerability in the results of these studies. In these situations, investigators should either conduct sensitivity analysis on such assumptions, or preferably, use comparator cohorts (which avoids the need to make such assumptions).
Further, in measuring economic outcomes that result from clinical pharmacy services, researchers must take into account the inflationary changes that occur over time. Health care costs, and especially pharmaceuticals, have seen exponential increases in recent years. For example, drug costs have risen 10%-20%/year over the past decade (from both price inflation and increased utilization). Interventions that produce absolute reductions in expenditures over long periods also might be credited with avoiding costs associated with inflation.
Future research should continue to be conducted in alternative practice sites and of contemporary types of pharmacy services. For example, a paucity of evidence exists on the economic impact of collaborative practice models, though clearly this is an important direction for the profession and should be addressed by future research. Also, relatively few articles exist on the interface between technology and clinical pharmacy services. As technology is implemented (either in drug distribution or to assist in provision of clinical services), the premise is that time is freed up for pharmacists to provide more patient care. However, few evaluative studies have been conducted to demonstrate this. Finally, it would be useful if a national or international agenda for this type of research were promoted by a representative group of pharmacy organizations to ensure that studies are conducted in practice sites and of the types of pharmacy services for which data are lacking. This effort would facilitate the availability of information that might support coordinated efforts to seek reimbursement of clinical pharmacy services.
The future success of pharmaceutical care models is increasingly dependent on our ability to provide compelling evidence of the value of clinical pharmacy services and to articulate that value to financial decision makers. The rising rate of inflation for pharmaceuticals, driven by the increasing age of our population and dramatic advances in pharmaceutical technology, has made drug resource consumption the most common cost containment target for health care systems. As across-the-board cuts are demanded of pharmacy departments, pharmacy leaders often are faced with the choice of reducing drug expenses or labor costs. Whereas limiting inefficient drug use may partially achieve the required cost containment, pharmacy managers must both articulate and provide evidence of the value of clinical pharmacy services so as to protect, or even expand, existing positions. The impact that clinical pharmacy services have by reducing overall health care expenses and improving patient outcomes should be fundamental to this message.
Studies of the cost impact of clinical pharmacy services have provided encouraging results, but we must continue to remain prepared to defend our participation in the care delivery process. We must improve both the quantity and quality of studies examining the value of clinical pharmacy services, raise the level of awareness and understanding of that research, and continue to find new ways to contribute to the health and well-being of patients; and this should be done in a manner that is convincing to health care decision makers.
Conclusion
The summarized data provide evidence of the economic benefit of clinical pharmacy services based on literature published between 1996 and 2000. The body of evidence on this topic has become more diverse, includes more contemporary practice sites and types of services, and has improved in the strength of study design and methodology. The information described in this article will assist pharmacy practitioners and managers in assessing both the costs to provide clinical pharmacy services and the anticipated economic benefits of such services. Our recommendations for future research may further enhance the strength of evidence of this literature and the conclusions that may be drawn from it.
Appendix 1. Fifty-nine Articles Included in This Review by Setting of Evaluation and Type of Clinical Pharmacy Service
Objective Pharmacy drug cost/resident day Despite a reduction in the number of drug doses/day after the intervention, there was an overall increase in pharmacy drug cost/resident day (65%).
Clinical outcomes also measured, methodology not well described, components of "pharmacy cost" not defined.
Community pharmacy Disease management
To evaluate the impact of clinical pharmacy services in a community pharmacy on blood pressure control, quality of life, patient satisfaction, quality of care, and cost of care 68 
OA
Control group
None Change in physician office visits and prescriptions and associated charges Charges associated with office visits and drugs were higher in the intervention than in the control group (mean total charges $1106 vs $526), though the intervention group had more comorbid conditions.
Clinical and humanistic outcomes also measured, no consideration of costs to provide service, conducted at multiple sites.
To evaluate the economic impact of pharmacist interventions using a disease management model in a retail pharmacy for patients with diabetes, hypertension, asthma, or hyperlipidemia 69 
OA
Control group
None Medical and prescription utilization and costs After controlling for age, comorbid conditions, and disease severity, total costs (medical and prescription claims) were lower in the intervention group ($723 vs $1017/patient/mo), while prescription costs did not differ during the 17-mo study.
Did not include cost to provide service in the analysis but stated it in the Discussion, did not discount dollar values over study period, conducted at multiple sites.
